Literature DB >> 33301642

The role of the SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma.

Motoyuki Tsuda1,2, Akihisa Fukuda1, Munenori Kawai1, Osamu Araki1, Hiroshi Seno1.   

Abstract

ATP-dependent chromatin remodeling complexes are a group of epigenetic regulators that can alter the assembly of nucleosomes and regulate the accessibility of transcription factors to DNA in order to modulate gene expression. One of these complexes, the SWI/SNF chromatin remodeling complex is mutated in more than 20% of human cancers. We have investigated the roles of the SWI/SNF complex in pancreatic ductal adenocarcinoma (PDA), which is the most lethal type of cancer. Here, we reviewed the recent literature regarding the role of the SWI/SNF complex in pancreatic tumorigenesis and current knowledge about therapeutic strategies targeting the SWI/SNF complex in PDA. The subunits of the SWI/SNF complex are mutated in 14% of human PDA. Recent studies have shown that they have context-dependent oncogenic or tumor-suppressive roles in pancreatic carcinogenesis. To target its tumor-suppressive properties, synthetic lethal strategies have recently been developed. In addition, their oncogenic properties could be novel therapeutic targets. The SWI/SNF subunits are potential therapeutic targets for PDA, and further understanding of the precise role of the SWI/SNF complex subunits in PDA is required for further development of novel strategies targeting SWI/SNF subunits against PDA.
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Entities:  

Keywords:  BAF; SWI/SNF; chromatin remodeling complexes; epigenetics; pancreatic ductal adenocarcinoma

Year:  2020        PMID: 33301642     DOI: 10.1111/cas.14768

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  7 in total

1.  BRD9 Bifunctional Degraders for Treating Cancer.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-11-06       Impact factor: 4.345

Review 2.  Integration of Epigenetic Mechanisms into Non-Genotoxic Carcinogenicity Hazard Assessment: Focus on DNA Methylation and Histone Modifications.

Authors:  Daniel Desaulniers; Paule Vasseur; Abigail Jacobs; M Cecilia Aguila; Norman Ertych; Miriam N Jacobs
Journal:  Int J Mol Sci       Date:  2021-10-11       Impact factor: 5.923

3.  Novel Compounds for Targeted Degradation of BRD9 and Their Use for Treating Cancer.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-12-08       Impact factor: 4.345

Review 4.  The Role of Epigenetic Modifications in Human Cancers and the Use of Natural Compounds as Epidrugs: Mechanistic Pathways and Pharmacodynamic Actions.

Authors:  Abdelhakim Bouyahya; Hamza Mechchate; Loubna Oumeslakht; Ikrame Zeouk; Sara Aboulaghras; Abdelaali Balahbib; Gokhan Zengin; Mohammad Amjad Kamal; Monica Gallo; Domenico Montesano; Nasreddine El Omari
Journal:  Biomolecules       Date:  2022-02-25

Review 5.  Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma.

Authors:  Daniel C Osei-Bordom; Gagandeep Sachdeva; Niki Christou
Journal:  Front Med (Lausanne)       Date:  2022-01-14

6.  SNAIL2 contributes to tumorigenicity and chemotherapy resistance in pancreatic cancer by regulating IGFBP2.

Authors:  Kenji Masuo; Ru Chen; Akitada Yogo; Aiko Sugiyama; Akihisa Fukuda; Toshihiko Masui; Shinji Uemoto; Hiroshi Seno; Shigeo Takaishi
Journal:  Cancer Sci       Date:  2021-10-20       Impact factor: 6.716

7.  SMARCC1 Suppresses Tumor Progression by Inhibiting the PI3K/AKT Signaling Pathway in Prostate Cancer.

Authors:  Zhao-Ming Xiao; Dao-Jun Lv; Yu-Zhong Yu; Chong Wang; Tao Xie; Tao Wang; Xian-Lu Song; Shan-Chao Zhao
Journal:  Front Cell Dev Biol       Date:  2021-06-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.